Activity of cetuximab as single agent in a patient with relapsed multiple myeloma. - Suppr | 超能文献

Activity of cetuximab as single agent in a patient with relapsed multiple myeloma.

作者信息

Böll Boris, Eichenauer Dennis A, Von Tresckow Bastian, Peine Denissa, Hallek Michael, Engert Andreas, Hübel Kai

出版信息

Leuk Lymphoma. 2010 Mar;51(3):562-4. doi: 10.3109/10428190903580428.

DOI:10.3109/10428190903580428

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Activity of cetuximab as single agent in a patient with relapsed multiple myeloma.

Leuk Lymphoma. 2010 Mar;51(3):562-4. doi: 10.3109/10428190903580428.

2

Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.抗表皮生长因子受体抗体西妥昔单抗用于难治性或复发性多发性骨髓瘤：一项II期前瞻性临床试验

Leuk Lymphoma. 2014 Mar;55(3):695-7. doi: 10.3109/10428194.2013.809074. Epub 2013 Jul 29.

3

Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.用于治疗骨髓瘤的单克隆抗体：靶向信号淋巴细胞激活分子家族成员7（SLAMF7）和CD38

Cancer J. 2016 Jan-Feb;22(1):3-6. doi: 10.1097/PPO.0000000000000172.

4

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.美妥昔单抗和西妥昔单抗可激活表皮生长因子受体，但无法通过Akt或Erk触发下游信号传导。

Int J Cancer. 2008 Apr 1;122(7):1530-8. doi: 10.1002/ijc.23253.

5

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.IPH2101进行泛KIR2D阻断治疗冒烟型多发性骨髓瘤的II期试验。

Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21.

6

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.抗KIR抗体IPH2101与来那度胺治疗复发/难治性多发性骨髓瘤患者的I期试验

Clin Cancer Res. 2015 Sep 15;21(18):4055-61. doi: 10.1158/1078-0432.CCR-15-0304. Epub 2015 May 21.

7

Multiple Myeloma Gets Three New Drugs.多发性骨髓瘤迎来三种新药。

Cancer Discov. 2016 Jan;6(1):4. doi: 10.1158/2159-8290.CD-NB2015-169. Epub 2015 Dec 9.

8

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.抗胰岛素样生长因子1受体（IGF-1R）单克隆抗体AVE1642单药及联合硼替佐米用于复发多发性骨髓瘤患者的I期研究

Leukemia. 2011 May;25(5):872-4. doi: 10.1038/leu.2011.4. Epub 2011 Feb 15.

9

[Daratumumab for multiple myeloma].达雷妥尤单抗用于治疗多发性骨髓瘤

Bull Cancer. 2018 Nov;105(11):985-991. doi: 10.1016/j.bulcan.2018.09.003. Epub 2018 Oct 24.

10

Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma.复发难治性骨髓瘤患者使用抗白细胞介素-6单克隆抗体CNTO 328单药治疗实现完全缓解。

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):333-7. doi: 10.1016/j.clml.2012.12.010. Epub 2013 Jan 10.

引用本文的文献

1

Multiple myeloma emerging after prolonged gefitinib treatment for non-small cell lung carcinoma.在对非小细胞肺癌进行长时间吉非替尼治疗后出现的多发性骨髓瘤。

Case Rep Oncol. 2011 Apr 6;4(1):198-203. doi: 10.1159/000327689.